Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19.

ABSTRACT:

Introduction

A novel coronavirus, designated SARS-CoV-2, caused an international outbreak of a respiratory illness, termed COVID-19 in December 2019. There is a lack of specific therapeutic agents based on evidence for this novel coronavirus infection; however, several medications have been evaluated as a potential therapy. Therapy is required to treat symptomatic patients and decrease the virus carriage duration to limit the communitytransmission.

Methods and analysis

We hypothesise that patients with mild COVID-19 treated with favipiravir will have a shorter duration of time to virus clearance than the control group. The primary outcome is to evaluate the effect of favipiravir on the timing of the PCR test conversion from positive to negative within 15 days after starting

SUBMITTER: Bosaeed M 

PROVIDER: S-EPMC8053307 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature